GLAUKOS Corp (GKOS) company profile
Close on Nov 17, 2026Market cap $14.40BP/E –Yield –
About Glaukos
Surgical & Medical Instruments & Apparatus, SIC 3841
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio and pipeline include micro-invasive glaucoma surgery devices such as iStent, iStent inject W, and iStent infinite, sustained-release pharmaceuticals including iDose TR, and corneal health treatments such as Photrexa and Epioxa. The company operates in key therapeutic areas centered on glaucoma and corneal health, serving ophthalmic surgeons and specialized eye care professionals.
The company conducts business domestically within the United States and across international markets, with operations and regulatory activities spanning countries such as the United Kingdom, Germany, France, and Japan. Glaukos operates facilities in locations including Burlington, Massachusetts, and Aliso Viejo, California, with its principal executive offices and global headquarters situated in Aliso Viejo, California.
Summary of the business section of Glaukos's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GLAUKOS Corp
- Headquarters
- Aliso Viejo, CA
- Address
- 1 Glaukos Way 92656
- Phone
- (949) 367-9600
- Website
- glaukos.com
- Employees
- 1,094, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Irvine, California
Stock & identifiers
- Ticker
- GKOS
- Exchange
- NYSE
- IPO date
- Jun 25, 2015
- Shares outstanding
- 59M, Oct 26, 2026
- Public float
- $5.91B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1192448
- CUSIP
- 377322102
- ISIN
- US3773221029
- FIGI
- BBG000WG2LQ1
- Share class FIGI
- BBG001T91NX8
- LEI
- 5299004JA1LHE21M6T14
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas William Burns | CHAIRMAN & CEO, Director | 1,768,667 |
| Joseph E. Gilliam | PRESIDENT & COO | 71,602 |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 37,328 |
| Alex R. Thurman | SVP & CHIEF FINANCIAL OFFICER | 63,906 |
| Gilbert H. Kliman | Director | 42,608 |
| Aimee S. Weisner | Director | 49,688 |
| Leana Wen | Director | 21,092 |
| Denice Torres | Director | 24,212 |
| David F. Hoffmeister | Director | 87,725 |
| Marc Stapley | Director | 39,327 |
| Mark J. Foley | Director | 60,267 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $12.03M | $9.99M | $4.71M | $150 | $78 |
| FY2024 | $9.03M | $25.16M | $3.13M | $199 | $78 |
| FY2023 | $8.65M | $22.35M | $3.04M | $106 | $76 |
| FY2022 | $6.27M | $5.46M | $2.93M | $58 | $78 |
| FY2021 | $7.26M | -$172.51K | $2.20M | $59 | $106 |
| FY2020 | $6.02M | $11.77M | $2.16M | $138 | $131 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Thomas W. Burns Chairman and Chief Executive Officer | $850.00K | $7.65M | $3.53M | – | $6.64K | $12.03M | +33% |
| Joseph E. Gilliam President and Chief Operating Officer | $584.85K | $6.50M | – | $689.01K | $11.75K | $7.79M | +87% |
| Alex R. Thurman Senior Vice President and Chief Financial Officer | $486.20K | $2.44M | – | – | $15.75K | $2.94M | +20% |
| Tomas Navratil Senior Vice President and Chief Development Officer | $499.40K | $2.40M | – | $504.29K | $11.75K | $3.42M | +23% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 25, 2015
- Offer price
- $18.00
- Securities offered
- 6,000,000
- Gross proceeds
- $108.00M
- Exchange
- NYSE
- First trading day
- Jun 25, 2015
- First-day close
- $31.22+73.4%
- Lock-up ends (est.)
- Dec 22, 2015
“The initial public offering price is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,094 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 21, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 17, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 12, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 30, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 25, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 22, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?